设计GLP-1输送:优化治疗的结构观点和配方方法
Ravi Vamsi Peri1, Harsh Anchan2, Kamal Jonnalagadda2
1Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA, USA. periravivamsi@gmail.com.
Nutrition & diabetes
|November 23, 2025
概括
类似于葡萄糖类-1 (GLP-1) 的类似物为代谢障碍提供了双重好处,将血糖控制与减肥相结合. 修改和提前交付可以提高它们的治疗效果和持续时间.
科学领域:
- 内分泌学和新陈代谢学
- 药理学和制药科学 药理学和制药科学
背景情况:
- 类似葡萄糖类-1 (GLP-1) 是代谢调节的关键激素,但其临床使用因被二类酶-IV (DPP-IV) 快速降解而受到限制.
- 短半衰期和不稳定性对有效治疗本源GLP-1在治疗代谢障碍中的应用构成挑战.
研究的目的:
- 审查GLP-1的起源,分泌和限制.
- 探索各种修改策略和传递系统,旨在增强GLP-1类型的药理动力学特征和疗效.
- 为开发更好的代谢障碍治疗方法提供见解.
主要方法:
- 探索GLP-1的生理作用和降解途径.
- 综述各种化学修饰技术:N和C端修饰,脂肪酸侧链修饰和大分子结合.
- 对GLP-1类似物持续和受控释放的优化输送策略的分析.
主要成果:
- 结构修改显著改善GLP-1模拟半衰期,稳定性,受体结合亲和力和生物活性.
- 脂肪酸结合和大分子结合是延长GLP-1模拟作用的有效策略.
- 优化的输送系统对于实现持续的治疗效果至关重要.
结论:
- 化学修饰和先进的输送系统已经成功克服了原生GLP-1的局限性.
- GLP-1类似物代表了代谢障碍的有希望的治疗途径,提供血糖控制和体重管理.
- 这一领域的持续研究有可能开发出更有效,更为患者友好的代谢健康治疗方法.
相关概念视频
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Insulin Formulations: Types and Delivery
626
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
626
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Biopharmaceutical Factors Influencing Drug Product Design: Overview
222
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
222
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
161
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
161
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185


